The State Health Supervision Bureau has issued a notice that in order to effectively prevent and control epidemic diseases at this stage, the cost of purchasing novel coronavirus disease detection reagents in designated retail pharmacies can be paid by personal accounts.

According to the disease detection standards of COVID-19, in accordance with these measures, novel coronavirus antigen detection reagents and corresponding detection items will be temporarily included in the provincial basic medical insurance medical service catalogue, and the price policy of public medical institutions will be continuously adjusted and optimized to provide COVID-19 antigen detection services. According to the relevant requirements, the provincial medical insurance department will include the drugs in the treatment plan of novel coronavirus into the payment scope of the medical insurance fund of this province. Drugs transferred from the latest diagnosis and treatment plan that are not included in the basic medical insurance catalogue.

Support the normal operation of medical institutions in the hardest hit areas, and advance part of the COVID-19 treatment fund according to procedures when necessary. In order to ensure the cost of vaccination in COVID-19, the price policy of nucleic acid and antigen testing items should be implemented. Long-term prescription policy, network diagnosis and treatment policy. Enhance resistance and establish immune barrier through active vaccine immunization. But from an international perspective, some countries choose? Lie flat? These are two kinds of immunity. Through the natural immunity of novel coronavirus disease, that is, group infection, through live vaccine immunization.

In particular, the whole vaccination rate and enhanced vaccination rate are not high enough to form a solid immune barrier, which is bound to make a large number of elderly people, vulnerable groups and susceptible people. We must adhere to the dynamic clean-up policy and unswervingly adhere to our strategies and measures, which is also a time window for us. If we strengthen vaccination and speed up scientific research and development, including drug research and vaccine research and development, I think we may also have a chance. Perhaps Omicron has changed, becoming gentler, with lower transmission rate and incidence. This is our best chance. Therefore, at this stage, we adhere to the overall strategy and policy unchanged. This should be the best choice, and it is also in line with the reality of epidemic prevention in China.